Adaptimmune Therapeutics (ADAP) Earnings Date & Reports

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

ADAP is expected to report earnings to rise 172.67% to -8 cents per share on August 06

Adaptimmune Therapeutics ADAP Stock Earnings Reports

Q2'25

Est.

$-0.08

Q1'25

Beat

by $0.09

Q4'24

Missed

by $0.02

Q3'24

Est.

$-0.01

Q2'24

Beat

by $0.09

The last earnings report on May 13 showed earnings per share of -2 cents, beating the estimate of -11 cents. With 19.45M shares outstanding, the current market capitalization sits at 65.98M.

View a ticker or compare two or three

Compare

ADAP